Sun’s Specialty Gambit Paying Off, Tildrakizumab Nears Sales Milestone
About 9,000 US physicians have prescribed Winlevi
Executive Summary
Tildrakizumab, including Ilumetri end market numbers, nears $500m sales mark, with the contribution of Sun's wider specialty business nearly doubling since fiscal 2018. The anti-IL-23p19 monoclonal antibody has seen global sales spurt 81% in fiscal 2022, while acne therapy Winlevi has been well received by dermatologists in the US.
You may also be interested in...
Sun Grapples With Impact Of Halol FDA Import Alert
Sun Pharma’s Halol facility has been placed under an import alert by the FDA following an inspection earlier this year that uncovered GMP deficiencies.
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Who’s Hired? Makov To Step Away From Sun Pharma After 10 Years
While Israel Makov steps away from Sun Pharmaceuticals, Mayne and Avet bring in new executives, Amneal appoints a new director and the AAM promotes a loyal colleague.